Anticholinergics in Palliative Medicine: An Update

Eric Prommer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Anticholinergics, or antimuscarinic drugs, are drugs that competitively inhibit the action of acetylcholine at muscarinic receptors, leading to a blockade of the actions of the parasympathetic nervous system at sites where overactivity can lead to increased symptom burden. Successful blockade of the parasympathetic nervous system ultimately leads to decreased production of secretions in the salivary, bronchial, and gastrointestinal tracts. These effects are often used for several symptoms that originate due to parasympathetic nervous system overactivity, such as the "death rattle" and malignant bowel obstruction. Anticholinergic agents are divided into either tertiary amines or quaternary ammonium compounds, which differ in their ability to cross into the central nervous system. Quaternary compounds do not cross into the central nervous system and have a different adverse effect profile than the tertiary amines. The purpose of this review is to highlight anticholinergic agents, their pharmacology, and an evidence-based assessment of their role in palliative care.

Original languageEnglish (US)
Pages (from-to)490-498
Number of pages9
JournalAmerican Journal of Hospice and Palliative Medicine
Volume30
Issue number5
DOIs
StatePublished - Aug 2013

Fingerprint

Parasympathetic Nervous System
Cholinergic Antagonists
Amines
Central Nervous System
Quaternary Ammonium Compounds
Muscarinic Antagonists
Muscarinic Receptors
Palliative Care
Pharmaceutical Preparations
Gastrointestinal Tract
Pharmacology
Palliative Medicine

Keywords

  • binding affinities
  • death rattle
  • malignant bowel obstruction
  • muscarinic
  • receptors
  • secretions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Anticholinergics in Palliative Medicine : An Update. / Prommer, Eric.

In: American Journal of Hospice and Palliative Medicine, Vol. 30, No. 5, 08.2013, p. 490-498.

Research output: Contribution to journalArticle

@article{08328a07aa924e539af0c28a7368c069,
title = "Anticholinergics in Palliative Medicine: An Update",
abstract = "Anticholinergics, or antimuscarinic drugs, are drugs that competitively inhibit the action of acetylcholine at muscarinic receptors, leading to a blockade of the actions of the parasympathetic nervous system at sites where overactivity can lead to increased symptom burden. Successful blockade of the parasympathetic nervous system ultimately leads to decreased production of secretions in the salivary, bronchial, and gastrointestinal tracts. These effects are often used for several symptoms that originate due to parasympathetic nervous system overactivity, such as the {"}death rattle{"} and malignant bowel obstruction. Anticholinergic agents are divided into either tertiary amines or quaternary ammonium compounds, which differ in their ability to cross into the central nervous system. Quaternary compounds do not cross into the central nervous system and have a different adverse effect profile than the tertiary amines. The purpose of this review is to highlight anticholinergic agents, their pharmacology, and an evidence-based assessment of their role in palliative care.",
keywords = "binding affinities, death rattle, malignant bowel obstruction, muscarinic, receptors, secretions",
author = "Eric Prommer",
year = "2013",
month = "8",
doi = "10.1177/1049909112459366",
language = "English (US)",
volume = "30",
pages = "490--498",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Anticholinergics in Palliative Medicine

T2 - An Update

AU - Prommer, Eric

PY - 2013/8

Y1 - 2013/8

N2 - Anticholinergics, or antimuscarinic drugs, are drugs that competitively inhibit the action of acetylcholine at muscarinic receptors, leading to a blockade of the actions of the parasympathetic nervous system at sites where overactivity can lead to increased symptom burden. Successful blockade of the parasympathetic nervous system ultimately leads to decreased production of secretions in the salivary, bronchial, and gastrointestinal tracts. These effects are often used for several symptoms that originate due to parasympathetic nervous system overactivity, such as the "death rattle" and malignant bowel obstruction. Anticholinergic agents are divided into either tertiary amines or quaternary ammonium compounds, which differ in their ability to cross into the central nervous system. Quaternary compounds do not cross into the central nervous system and have a different adverse effect profile than the tertiary amines. The purpose of this review is to highlight anticholinergic agents, their pharmacology, and an evidence-based assessment of their role in palliative care.

AB - Anticholinergics, or antimuscarinic drugs, are drugs that competitively inhibit the action of acetylcholine at muscarinic receptors, leading to a blockade of the actions of the parasympathetic nervous system at sites where overactivity can lead to increased symptom burden. Successful blockade of the parasympathetic nervous system ultimately leads to decreased production of secretions in the salivary, bronchial, and gastrointestinal tracts. These effects are often used for several symptoms that originate due to parasympathetic nervous system overactivity, such as the "death rattle" and malignant bowel obstruction. Anticholinergic agents are divided into either tertiary amines or quaternary ammonium compounds, which differ in their ability to cross into the central nervous system. Quaternary compounds do not cross into the central nervous system and have a different adverse effect profile than the tertiary amines. The purpose of this review is to highlight anticholinergic agents, their pharmacology, and an evidence-based assessment of their role in palliative care.

KW - binding affinities

KW - death rattle

KW - malignant bowel obstruction

KW - muscarinic

KW - receptors

KW - secretions

UR - http://www.scopus.com/inward/record.url?scp=84881110935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881110935&partnerID=8YFLogxK

U2 - 10.1177/1049909112459366

DO - 10.1177/1049909112459366

M3 - Article

C2 - 22964342

AN - SCOPUS:84881110935

VL - 30

SP - 490

EP - 498

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 5

ER -